PURPOSE: To evaluate the safety and efficacy of once-daily intraclot injections of low doses (≤ 10 mg) of tissue plasminogen activator (tPA) for thrombolysis of venous thrombosis. MATERIALS AND METHODS: In prospective studies, 33 patients with subclavian, jugular, and central venous thrombosis (SJ-CVT) (all but two cases associated with central catheters) were treated once a day with ≤ 4 mg/day of tPA, and 30 patients with acute deep vein thrombosis of the lower extremity (DVT-LE) < 14 days old were treated once a day with ≤ 10 mg/leg/day of tPA by intraclot "lacing" of thrombus without continuous infusions of tPA. RESULTS: Patency was restored in 26 (79%) of 33 patients with SJ-CVT using an average total dose of 7.1 mg of tPA/per patient and average of 2.1 treatments or days of therapy. Five patients received thrombolytic therapy for SJ-CVT as outpatients. Initial patency was restored in 29 (97%) of 30 patients with acute DVT-LE using an average total dose of 20 mg of tPA per patient over an average of 2.7 treatments/or days per patient. Follow-up imaging examinations at 6 months showed continued patency in 27 (96%)/of 28 patients. There were no major bleeding complications, and no patient required a blood transfusion. CONCLUSIONS: Intraclot injection of low doses of alteplase is effective for acute venous thrombosis, and pharmacokinetic data suggest potentially greater safety.
PURPOSE: To evaluate the safety and efficacy of once-daily intraclot injections of low doses (≤ 10 mg) of tissue plasminogen activator (tPA) for thrombolysis of venous thrombosis. MATERIALS AND METHODS: In prospective studies, 33 patients with subclavian, jugular, and central venous thrombosis (SJ-CVT) (all but two cases associated with central catheters) were treated once a day with ≤ 4 mg/day of tPA, and 30 patients with acute deep vein thrombosis of the lower extremity (DVT-LE) < 14 days old were treated once a day with ≤ 10 mg/leg/day of tPA by intraclot "lacing" of thrombus without continuous infusions of tPA. RESULTS: Patency was restored in 26 (79%) of 33 patients with SJ-CVT using an average total dose of 7.1 mg of tPA/per patient and average of 2.1 treatments or days of therapy. Five patients received thrombolytic therapy for SJ-CVT as outpatients. Initial patency was restored in 29 (97%) of 30 patients with acute DVT-LE using an average total dose of 20 mg of tPA per patient over an average of 2.7 treatments/or days per patient. Follow-up imaging examinations at 6 months showed continued patency in 27 (96%)/of 28 patients. There were no major bleeding complications, and no patient required a blood transfusion. CONCLUSIONS: Intraclot injection of low doses of alteplase is effective for acute venous thrombosis, and pharmacokinetic data suggest potentially greater safety.
Authors: D Vlassopoulos; E Logothetis; D Arvanitis; C Noussias; P Magana; K Katopodis; V Hadjiconstantinou Journal: Clin Nephrol Date: 1996-07 Impact factor: 0.975
Authors: V J Marder; B Brenner; S Totterman; C W Francis; R Rubin; A K Rao; C M Kessler; H C Kwaan; G V Sharma; K L Fong Journal: J Lab Clin Med Date: 1992-05
Authors: H Bjarnason; J R Kruse; D A Asinger; G K Nazarian; C A Dietz; M D Caldwell; N S Key; A T Hirsch; D W Hunter Journal: J Vasc Interv Radiol Date: 1997 May-Jun Impact factor: 3.464
Authors: David Yi Zhang; Jay Lozier; Richard Chang; Vandana Sachdev; Marcus Y Chen; Jennifer L Audibert; Keith A Horvath; Douglas R Rosing Journal: Int J Cardiol Date: 2011-10-14 Impact factor: 4.164
Authors: Richard Chang; John A Butman; Russell R Lonser; Richard M Sherry; Prakash K Pandalai; McDonald K Horne; Jay N Lozier Journal: J Vasc Interv Radiol Date: 2013-01 Impact factor: 3.464